Immunic in-licenses research from Goettingen Medical Center

22 September 2021
immunic_large-1

Oral immunology therapy specialist Immunic (Nasdaq: IMUX) has executed an in-licensing deal with the University Medical Center Goettingen, Germany.

The company is developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases.

The agreement covers the combination of DHODH inhibitors and nucleoside analogs to treat viral infections, including COVID-19 and influenza.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical